# Veru Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Veru Inc). ## Overview Veru Inc. is a U.S.-based biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. Its pipeline centers on enobosarm, an oral selective androgen receptor modulator, and sabizabulin, an oral microtubule disruptor, with development activities directed from the United States. ## Products & services • Enobosarm for obesity-related lean mass preservation • Sabizabulin for atherosclerosis inflammation • Clinical development of late-stage drug candidates • Regulatory, trial design, and commercialization planning - **Enobosarm obesity program** (50%) — Development of enobosarm as an oral SARM to preserve muscle and bone while reducing fat in obesity treatment. - **Sabizabulin atherosclerosis inflammation program** (50%) — Development of sabizabulin for inflammation-driven cardiovascular risk reduction in stable coronary artery disease. - Enobosarm for obesity-related lean mass preservation - Sabizabulin for atherosclerosis inflammation - Clinical development of late-stage drug candidates - Regulatory, trial design, and commercialization planning ## Customers Veru does not sell a broad commercial product portfolio today; its primary counterparties are clinical investigators, research sites, regulators, and future healthcare buyers for approved medicines. If its candidates reach market, the end customers would be physicians, hospitals, and patients in obesity and cardiovascular disease settings. - **Clinical trial ecosystem** (primary) — Research sites, investigators, and CRO-like partners that support development of enobosarm and sabizabulin. - **Regulatory authorities** (primary) — FDA and other agencies that evaluate clinical and safety data before any commercialization. - **Physicians and specialty clinics** (secondary) — Potential prescribers for obesity and cardiovascular indications if the drug candidates are approved. - **Patients with obesity or coronary disease** (secondary) — End users of the therapies, especially patients needing weight-loss support with lean-mass preservation or inflammation reduction. - Clinical trial sites and investigators running enobosarm studies - Regulators reviewing safety and efficacy data for approval - Physicians treating obesity and cardiometabolic disease - Hospitals and specialty clinics managing cardiovascular patients - Future patients needing oral therapies for chronic disease ## Geography Veru is headquartered in the United States and conducts its development work from there. Its drug candidates are intended for global pharmaceutical markets, with competition and regulatory pathways spanning North America, Europe, and other regions. - Headquartered and operated from the United States - Clinical development and regulatory work are U.S.-centered - Future commercialization could extend to North America and Europe - Competitive landscape includes global pharma and biotech firms ## Strategy Veru’s strategy is to advance a small number of late-stage drug candidates with differentiated mechanisms in large cardiometabolic markets. The company is prioritizing clinical execution, regulatory progress, and eventual commercialization planning around enobosarm and sabizabulin. - **Advance enobosarm clinical development** (short-term) — Enobosarm is the company’s most visible obesity-related asset and targets a large unmet need. - **Develop sabizabulin for inflammatory cardiovascular disease** (medium-term) — Sabizabulin provides a second late-stage program and broadens the pipeline beyond obesity. - **Maintain optionality for commercialization** (medium-term) — Any approved asset would require launch readiness, market access, and physician adoption. - Advance enobosarm through planned Phase 2b development - Progress sabizabulin in cardiovascular inflammation studies - Focus on differentiated oral therapies for large chronic diseases - Use management expertise in urology, oncology, and drug development - Prepare for regulatory and launch planning if data support approval ## Risks Veru faces the typical risks of a late-stage biopharmaceutical developer: clinical failure, regulatory delay, and commercialization uncertainty. It also competes against much larger pharmaceutical companies in obesity and cardiovascular disease, while needing external capital to fund development and operations. - **No current commercial revenue base** [critical] — After the FC2 business sale, the company depends on future approvals to generate product revenue. - **Clinical development risk** [high] — Enobosarm and sabizabulin are still in development and may not demonstrate sufficient benefit-risk profiles. - **Competitive pressure in obesity and cardiometabolic markets** [high] — Major pharmaceutical companies and biotech firms have greater R&D, regulatory, and commercial resources. - **Financing and dilution risk** [high] — Development spending exceeds internal cash generation, so the company may need equity or debt financing. - **Intellectual property enforcement risk** [medium] — Protecting enobosarm-related IP may require litigation that is expensive and uncertain. - Clinical trials may fail to show efficacy or acceptable safety - Regulatory approval is uncertain and can be delayed - Large pharma competitors have greater resources and reach - The company depends on external financing to fund development - Intellectual property disputes could be costly and time-consuming ## Accounting The most important accounting judgments are R&D expense recognition, fair value measurements, and impairment testing for goodwill and intangibles. Because the company has limited commercial activity and has sold legacy assets, reported results can also be affected by gains or losses on asset sales, extinguishment of obligations, and discontinued operations. - **Research and development expense recognition** — Affects operating loss and comparability across quarters - **Fair value measurement** — Can create non-cash gains or losses in earnings - **Goodwill impairment** — Could lead to material non-cash impairment charges - **Discontinued operations and asset sale accounting** — Can separate legacy business results from continuing operations - R&D spending is expensed as programs advance through clinical trials - Fair value estimates affect equity securities and derivative liabilities - Goodwill impairment testing depends on future cash flow assumptions - Asset sale gains and discontinued operations can distort comparability - Share-based compensation affects SG&A and reported operating loss --- *Last updated: 2026-09-24T11:09:27.750040+00:00*